PeerVoice is an independent, professional medical publishing concern focused on gathering and reporting information pertaining to clinically relevant advances and developments in the science and practice of medicine. As publishers of PeerVoice Publications, PeerVoice is solely responsible for the selection of publication topics, the preparation of editorial content and the distribution of all materials it publishes.
http://www.peervoice.com
Novel Therapies for Patients With DLBCL: What Does the Future Hold?
Visit https://www.peervoice.com/VYU860 to view the entire programme with slides. After completing “Novel Therapies for Patients With DLBCL: What Does the Future Hold?”, participants will be able to: Explain the rationale for novel therapeutic options for patients with relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL); Evaluate the risk-benefit profiles of current and emerging therapies for the management of R/R DLBCL; and Incorporate available data on the use of novel anti-CD19 antibody strategies to treat R/R DLBCL into clinical practice.